Eli Lilly (LLY) stock under spotlight with $3B China investment, orforglipron approval filing, and LillyConnect platform launch. Analysts maintain bullish outlook.

It's been a tough start for Eli Lilly (NYSE: LLY) stock this year. Entering this week, the pharmaceutical giant's value has fallen by 8%. While its five-year gains are still impressive at around 380%, ...

In the latest close session, Eli Lilly (LLY) was up +1.82% at $1,008.39. This move outpaced the S&P 500's daily gain of 0.83%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq added 1.38%.

Novo Nordisk erases most gains since Wegovy's 2021 launch as Lilly's drugs outperform its therapies in clinical studies and price cuts loom across its core GLP-1 franchise.

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

March 9 () - Eli Lilly said on Monday a small number of basic Medicare drug ‌plans may not follow the $50 per month cap ‌on out-of-pocket costs for its weight-loss drugs, under the Medicare agency's ...

That's helped to supercharge Eli Lilly's (NYSE: LLY) growth and its stock price. However, you might be better off with this higher-yielding drug peer, even though it doesn't compete in the GLP-1 ...

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 24.72% on an annualized basis producing an average annual return of 36.42%. Currently, Eli Lilly has a market capitalization ...

Eli Lilly's market share in obesity drugs exceeds 60%, but further gains may be capped as competition escalates. Read why LLY ...

Jensen Investment Management, an asset management company based in the US, released its fourth-quarter investor letter for ...

Eli Lilly's soaring stock price has sparked 2026 split speculation. Here's what a potential LLY split could mean and what investors should consider now.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...